Market research
PRVL Prevail Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 788M
- P/E ratio
- Not available
- Analyst target
- 23.63
- Dividend yield
- 0.0%
- Beta
- Not available
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 788M
- P/E ratio
- Not available
- Analyst target
- 23.63
- Dividend yield
- 0.0%
- Beta
- Not available
About
About Prevail Therapeutics Inc
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Research context
Prevail Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PRVL discussion.
5 years, 6 months ago
Prevail Therapeutics Inc is currently in a long term uptrend where the price is trading 48.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Prevail Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 8.4% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.6% to $-17M since the same quarter in the previous year.
Based on the above factors, Prevail Therapeutics Inc gets an overall score of 4/5.